fluorouracil has been researched along with Dermatitis Medicamentosa in 121 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment." | 9.20 | Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. ( Han, Y; Shang, M; Shi, SB; Tian, J; Xu, J, 2015) |
| "This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients." | 9.14 | Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009) |
| "We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel." | 9.13 | Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients. ( Bosnjak, SM; Radulovic, S; Susnjar, S, 2008) |
| "We describe a 47-year-old man who developed a linear serpentine erythematous eruption, overlying the superficial veins on both arms, after treatment with intravenous 5-fluorouracil." | 8.80 | Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. ( Alomar, A; Lopez-Pousa, A; Pujol, RM; Rocamora, V; Taberner, R, 1998) |
| "This study is aimed to identify clinical predictors, other than HER2 overexpression, for the response to lapatinib plus capecitabine (LAPCAP) in patients with HER2-positive advanced breast cancer (HER2ABC)." | 7.80 | Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. ( Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S, 2014) |
| "A 42-year-old woman being treated with 5-fluorouracil for carcinoma of the sigmoid colon developed persistent serpentine supravenous hyperpigmented eruption (PSSHE), bilateral mottling of the palms and diffuse hyperpigmentation of the soles." | 7.80 | 5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. ( Agrawal, A; Parihar, A; Suvirya, S, 2014) |
| "It is well known that fluorouracil (FU) agents frequently induce discoid-lupus-erythematosus (DLE)-like eruptions and acral erythema in Japan." | 7.74 | Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. ( Adachi, A; Horikawa, T; Nagai, H, 2007) |
| "The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy." | 7.69 | Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997) |
| "Fluorouracil is a common cause of acral erythema and a variety of pigmentary anomalies." | 7.68 | Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease. ( Beard, JS; Skelton, HG; Smith, KJ, 1993) |
| " We should pay attention to the dosage of 5-FU and ActD, monitor adverse reactions strictly, to reduce occurrence of skin malignant events." | 6.82 | 5-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review. ( Li, T; Liu, Y; Wang, M; Wang, S; Wang, Y; Zhang, L; Zhang, X, 2022) |
| "The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible." | 6.73 | A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. ( Antonini, NF; Cats, A; Creemers, GJ; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Rodenburg, CJ; Schrama, JG; Tol, J; Vos, AH, 2008) |
| "Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2." | 6.45 | [Lapatinib treatment-option in trastuzumab-resistant breast cancer]. ( Pikó, B, 2009) |
| "5-Fluorouracil (5-FU) is an antineoplastic agent that is used topically to treat actinic keratoses." | 5.62 | Painful scrotal dermatitis secondary to topical 5-fluorouracil. ( Himes, RS; McKee, PH; Roberts, AA; Smith, RJ; Yi, JZ, 2021) |
| "A combination of cetuximab plus pemetrexed was marginally effective and well tolerated in patients with advanced esophageal squamous cell carcinoma as the second-line treatment." | 5.20 | Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. ( Han, Y; Shang, M; Shi, SB; Tian, J; Xu, J, 2015) |
| "This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients." | 5.14 | Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009) |
| "We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel." | 5.13 | Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients. ( Bosnjak, SM; Radulovic, S; Susnjar, S, 2008) |
| "We report on a 63-year-old female patient with breast cancer treated with epirubicin combination therapy." | 4.90 | Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature. ( Aigner, B; Arzberger, EJ; Bauernhofer, T; Niederkorn, A; Petru, E; Richtig, E, 2014) |
| "We describe a 47-year-old man who developed a linear serpentine erythematous eruption, overlying the superficial veins on both arms, after treatment with intravenous 5-fluorouracil." | 4.80 | Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. ( Alomar, A; Lopez-Pousa, A; Pujol, RM; Rocamora, V; Taberner, R, 1998) |
| "This study is aimed to identify clinical predictors, other than HER2 overexpression, for the response to lapatinib plus capecitabine (LAPCAP) in patients with HER2-positive advanced breast cancer (HER2ABC)." | 3.80 | Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. ( Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S, 2014) |
| "A 42-year-old woman being treated with 5-fluorouracil for carcinoma of the sigmoid colon developed persistent serpentine supravenous hyperpigmented eruption (PSSHE), bilateral mottling of the palms and diffuse hyperpigmentation of the soles." | 3.80 | 5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. ( Agrawal, A; Parihar, A; Suvirya, S, 2014) |
| " They had osteosarcoma in methotrexate group (n=7), gastrointestinal malignancies in 5FU group (n=9) and breast cancer in the capecitabine group (n=2)." | 3.78 | Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients. ( Akbulut, H; Demirkazik, A; Dincol, D; Dogan, M; Icli, F; Karabulut, HG; Tukun, A; Utkan, G; Yalcin, B, 2012) |
| "It is well known that fluorouracil (FU) agents frequently induce discoid-lupus-erythematosus (DLE)-like eruptions and acral erythema in Japan." | 3.74 | Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. ( Adachi, A; Horikawa, T; Nagai, H, 2007) |
| "The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy." | 3.69 | Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997) |
| "Fluorouracil is a common cause of acral erythema and a variety of pigmentary anomalies." | 3.68 | Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease. ( Beard, JS; Skelton, HG; Smith, KJ, 1993) |
| " Skin toxicity outcomes were collected using the Common Toxicity Criteria for Adverse Events version 3." | 3.01 | Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). ( Alberts, SR; Banbury, BL; Chan, AT; Cohen, SA; George, TJ; Goldberg, RM; Harrison, TA; Hua, X; Huyghe, JR; Labadie, JD; Newcomb, PA; Penney, KL; Peters, U; Phipps, AI; Shi, Q; Sinicrope, FA; Sun, W; Yothers, G, 2021) |
| "Cetuximab-induced skin rash Gd3+ occurs in ≥16% patients (pts) (Heinemann et al." | 2.84 | Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. ( Boller, E; Dingeldein, G; Ehscheidt, P; Flohr, T; Galle, PR; Geer, T; Göhler, T; Hebart, H; Heike, M; Indorf, M; Josten, KM; Karthaus, M; Lang, C; Moehler, M; Neise, M; Rudi, J; Schimanski, CC; Schmittel, A; Staib, F; Wierecky, J; Wörns, MA, 2017) |
| " We should pay attention to the dosage of 5-FU and ActD, monitor adverse reactions strictly, to reduce occurrence of skin malignant events." | 2.82 | 5-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review. ( Li, T; Liu, Y; Wang, M; Wang, S; Wang, Y; Zhang, L; Zhang, X, 2022) |
| "Erlotinib can be safely administered with adjuvant IMRT-based CRT and chemotherapy." | 2.78 | Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. ( Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L, 2013) |
| "The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible." | 2.73 | A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. ( Antonini, NF; Cats, A; Creemers, GJ; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Rodenburg, CJ; Schrama, JG; Tol, J; Vos, AH, 2008) |
| "Fluorouracil alone can cause a variety of dermatologic adverse effects; however, it is not considered to be a chemical vesicant." | 2.67 | Local tissue reaction to intravenous fluorouracil and leucovorin. ( Decker, DA; Fryer, NL; Umstead, GS, 1991) |
| "Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2." | 2.45 | [Lapatinib treatment-option in trastuzumab-resistant breast cancer]. ( Pikó, B, 2009) |
| "In patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) the estimated prognosis is usually poor." | 1.62 | Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study. ( Amorim, C; Domingues, I; Felix, R; Garcia, AR; João Sousa, M; Mariano, M; Pontes, F; Salgueiro, F; Teixeira, M, 2021) |
| "5-Fluorouracil (5-FU) is an antineoplastic agent that is used topically to treat actinic keratoses." | 1.62 | Painful scrotal dermatitis secondary to topical 5-fluorouracil. ( Himes, RS; McKee, PH; Roberts, AA; Smith, RJ; Yi, JZ, 2021) |
| "5 fluorouracil therapy was terminated and the patients were shifted to interferon therapy subsequently." | 1.51 | Severe necrotising inflammatory skin reaction to topical 5-fluorouracil. ( Gokhale, NS, 2019) |
| "Close monitoring and prompt discontinuation of the drugs with high volume of distribution and metabolized through the liver are necessary to avoid drug-drug interaction in liver transplant patients." | 1.40 | Liver injury possibly related to drug interaction after liver transplant: a case report. ( Jiang, WT; Liu, YH; Pan, C; Thian, Y; Zhu, LQ, 2014) |
| "The treatment of anal cancer is based on concomitant radiotherapy and chemotherapy and is associated with a nonnegligible rate of local severe toxicities that can strongly impair the quality of life." | 1.39 | Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy. ( Benezery, K; Doyen, J; Follana, P; Francois, E; Gal, J; Gérard, JP; Hannoun-Levi, JM; Ortholan, C, 2013) |
| "Necrolytic migratory erythema is an obligatory paraneoplastic syndrome." | 1.39 | Necrolytic migratory erythema in a patient with neuroendocrine carcinoma. ( Enk, AH; Gronau, M; Hassel, JC; Jäger, D, 2013) |
| "Twenty-one patients with inoperable colon cancer in the pelvis were treated with intra-arterial 5-fluorouracil (5-FU) and mitomycin C, given bilaterally into the internal iliac arteries." | 1.27 | Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin. ( Chuang, VP; Claghorn, L; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1985) |
| "Among 26 colorectal cancer patients assessable for response there was a 15." | 1.26 | Allopurinol modulation of fluorouracil toxicity. ( Fox, RM; Piper, AA; Sampson, D; Tattersall, MH; Woods, RL, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (28.10) | 18.7374 |
| 1990's | 18 (14.88) | 18.2507 |
| 2000's | 36 (29.75) | 29.6817 |
| 2010's | 27 (22.31) | 24.3611 |
| 2020's | 6 (4.96) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, S | 3 |
| Li, T | 3 |
| Wang, Y | 3 |
| Wang, M | 3 |
| Liu, Y | 3 |
| Zhang, X | 3 |
| Zhang, L | 3 |
| Soueidy, C | 1 |
| Skaff, S | 1 |
| Stephan, F | 1 |
| Kattan, J | 1 |
| Gokhale, NS | 1 |
| Labadie, JD | 1 |
| Hua, X | 1 |
| Harrison, TA | 1 |
| Banbury, BL | 1 |
| Huyghe, JR | 1 |
| Sun, W | 1 |
| Shi, Q | 1 |
| Yothers, G | 1 |
| Alberts, SR | 1 |
| Sinicrope, FA | 1 |
| Goldberg, RM | 1 |
| George, TJ | 1 |
| Penney, KL | 1 |
| Phipps, AI | 1 |
| Cohen, SA | 1 |
| Peters, U | 1 |
| Chan, AT | 1 |
| Newcomb, PA | 1 |
| Pontes, F | 1 |
| Garcia, AR | 1 |
| Domingues, I | 1 |
| João Sousa, M | 1 |
| Felix, R | 1 |
| Amorim, C | 1 |
| Salgueiro, F | 1 |
| Mariano, M | 1 |
| Teixeira, M | 1 |
| Béguin, J | 1 |
| Kohlhauer, M | 1 |
| Laloy, E | 1 |
| Degorce, F | 1 |
| Moreau, B | 1 |
| Quéméneur, É | 1 |
| Erbs, P | 1 |
| Klonjkowski, B | 1 |
| Maurey, C | 1 |
| Yi, JZ | 1 |
| Himes, RS | 1 |
| Smith, RJ | 2 |
| McKee, PH | 1 |
| Roberts, AA | 1 |
| Matsuda, K | 1 |
| Namiki, T | 1 |
| Ueno, M | 1 |
| Hashimoto, T | 1 |
| Hanafusa, T | 1 |
| Yokozeki, H | 1 |
| Hernandez-Aragues, I | 1 |
| Baniandrés-Rodríguez, O | 1 |
| Avilés-Izquierdo, JA | 1 |
| Vilas-Boas, PT | 1 |
| Nemer, KM | 1 |
| Solus, JF | 1 |
| Schaffer, A | 1 |
| Rosman, IS | 1 |
| Lee, SJ | 1 |
| Haas, M | 1 |
| Siveke, JT | 1 |
| Schenk, M | 1 |
| Lerch, MM | 1 |
| Caca, K | 1 |
| Freiberg-Richter, J | 1 |
| Fischer von Weikersthal, L | 1 |
| Kullmann, F | 1 |
| Reinacher-Schick, A | 1 |
| Fuchs, M | 1 |
| Kanzler, S | 1 |
| Kunzmann, V | 1 |
| Ettrich, TJ | 1 |
| Kruger, S | 1 |
| Westphalen, CB | 1 |
| Held, S | 1 |
| Heinemann, V | 1 |
| Boeck, S | 1 |
| Neal, DE | 1 |
| Aberbigbe, O | 1 |
| Etzkorn, JR | 1 |
| Senda, N | 1 |
| Miyagaki, T | 1 |
| Oka, T | 1 |
| Nonogaki, A | 1 |
| Yoshizaki, A | 1 |
| Shibata, S | 1 |
| Sato, S | 1 |
| Herman, JM | 1 |
| Fan, KY | 1 |
| Wild, AT | 1 |
| Hacker-Prietz, A | 1 |
| Wood, LD | 1 |
| Blackford, AL | 1 |
| Ellsworth, S | 1 |
| Zheng, L | 1 |
| Le, DT | 1 |
| De Jesus-Acosta, A | 1 |
| Hidalgo, M | 1 |
| Donehower, RC | 1 |
| Schulick, RD | 1 |
| Edil, BH | 1 |
| Choti, MA | 1 |
| Hruban, RH | 1 |
| Pawlik, TM | 1 |
| Cameron, JL | 1 |
| Laheru, DA | 1 |
| Wolfgang, CL | 1 |
| Doyen, J | 1 |
| Benezery, K | 1 |
| Follana, P | 1 |
| Ortholan, C | 1 |
| Gérard, JP | 1 |
| Hannoun-Levi, JM | 1 |
| Gal, J | 1 |
| Francois, E | 1 |
| Zhu, LQ | 1 |
| Jiang, WT | 1 |
| Pan, C | 1 |
| Liu, YH | 1 |
| Thian, Y | 1 |
| Taieb, J | 1 |
| Tabernero, J | 1 |
| Mini, E | 1 |
| Subtil, F | 1 |
| Folprecht, G | 1 |
| Van Laethem, JL | 1 |
| Thaler, J | 1 |
| Bridgewater, J | 1 |
| Petersen, LN | 1 |
| Blons, H | 1 |
| Collette, L | 1 |
| Van Cutsem, E | 1 |
| Rougier, P | 2 |
| Salazar, R | 1 |
| Bedenne, L | 1 |
| Emile, JF | 1 |
| Laurent-Puig, P | 1 |
| Lepage, C | 1 |
| Walker, G | 1 |
| Lane, N | 1 |
| Parekh, P | 1 |
| Araki, K | 1 |
| Fukada, I | 1 |
| Horii, R | 1 |
| Takahashi, S | 1 |
| Akiyama, F | 1 |
| Iwase, T | 1 |
| Ito, Y | 1 |
| Suvirya, S | 1 |
| Agrawal, A | 1 |
| Parihar, A | 1 |
| Aigner, B | 1 |
| Bauernhofer, T | 1 |
| Petru, E | 1 |
| Niederkorn, A | 1 |
| Arzberger, EJ | 1 |
| Richtig, E | 2 |
| Tian, J | 1 |
| Shang, M | 1 |
| Shi, SB | 1 |
| Han, Y | 1 |
| Xu, J | 1 |
| Imran, F | 1 |
| Harman, K | 1 |
| Pomerantz, H | 1 |
| Korgavkar, K | 1 |
| Lee, KC | 1 |
| Lew, R | 1 |
| Weinstock, MA | 1 |
| Fattouh, K | 1 |
| Collet-Benzaquen, D | 1 |
| Provensal, AM | 1 |
| Desseigne, F | 1 |
| Castillo, C | 1 |
| Combemale, P | 1 |
| de la Fouchardière, A | 1 |
| Schimanski, CC | 1 |
| Staib, F | 1 |
| Göhler, T | 1 |
| Hebart, H | 1 |
| Heike, M | 1 |
| Neise, M | 1 |
| Rudi, J | 1 |
| Geer, T | 1 |
| Dingeldein, G | 1 |
| Lang, C | 1 |
| Ehscheidt, P | 1 |
| Flohr, T | 1 |
| Josten, KM | 1 |
| Karthaus, M | 1 |
| Schmittel, A | 1 |
| Wierecky, J | 1 |
| Boller, E | 1 |
| Indorf, M | 1 |
| Wörns, MA | 1 |
| Galle, PR | 1 |
| Moehler, M | 1 |
| Piqué-Duran, E | 1 |
| Pérez-Díaz, MJ | 1 |
| Pérez-Cejudo, JA | 1 |
| Susnjar, S | 1 |
| Bosnjak, SM | 1 |
| Radulovic, S | 1 |
| Bajetta, E | 1 |
| Di Bartolomeo, M | 1 |
| Buzzoni, R | 1 |
| Ferrario, E | 1 |
| Dotti, KF | 1 |
| Mariani, L | 1 |
| Bajetta, R | 1 |
| Gevorgyan, A | 1 |
| Venturino, P | 1 |
| Galassi, M | 1 |
| Floristan, U | 1 |
| Feltes, RA | 1 |
| Sendagorta, E | 1 |
| Feito-Rodriguez, M | 1 |
| Ramírez-Marín, P | 1 |
| Vidaurrázaga, C | 1 |
| Casado-Jiménez, M | 1 |
| Gutiérrez-Pascual, M | 1 |
| Sols-Candela, M | 1 |
| Pinedo, F | 1 |
| López-Estebaranz, JL | 1 |
| Pikó, B | 1 |
| Black, JM | 1 |
| Hodari, KT | 1 |
| Rogers, N | 1 |
| Farris, PK | 1 |
| Lewis, AT | 1 |
| Boh, EE | 1 |
| Partl, R | 1 |
| Kapp, KS | 1 |
| Powers, R | 1 |
| Gordon, R | 1 |
| Roberts, K | 1 |
| Kovach, R | 1 |
| Kim, MY | 1 |
| Kang, SY | 1 |
| Lee, SY | 1 |
| Yang, MS | 1 |
| Kim, MH | 1 |
| Song, WJ | 1 |
| Kim, SH | 1 |
| Kim, YJ | 1 |
| Lee, KW | 1 |
| Cho, SH | 1 |
| Min, KU | 1 |
| Lee, JS | 1 |
| Kim, JH | 1 |
| Chang, YS | 1 |
| Dogan, M | 1 |
| Karabulut, HG | 1 |
| Tukun, A | 1 |
| Demirkazik, A | 1 |
| Utkan, G | 1 |
| Yalcin, B | 1 |
| Dincol, D | 1 |
| Akbulut, H | 1 |
| Icli, F | 1 |
| Sargen, M | 1 |
| Wanat, KA | 1 |
| Jambusaria, A | 1 |
| Rosenbach, M | 1 |
| Sobanko, J | 1 |
| Miller, CJ | 1 |
| Gronau, M | 1 |
| Jäger, D | 1 |
| Enk, AH | 1 |
| Hassel, JC | 1 |
| Bogenrieder, T | 1 |
| Weitzel, C | 1 |
| Schölmerich, J | 1 |
| Landthaler, M | 1 |
| Stolz, W | 1 |
| Wetzig, T | 1 |
| Beckheinrich, P | 1 |
| Rytter, M | 1 |
| Haustein, UF | 1 |
| Piguet, V | 1 |
| Borradori, L | 1 |
| Kirkup, ME | 1 |
| Narayan, S | 1 |
| Kennedy, CT | 1 |
| Bocci, G | 1 |
| Danesi, R | 1 |
| Allegrini, G | 1 |
| Innocenti, F | 1 |
| Di Paolo, A | 1 |
| Falcone, A | 1 |
| Conte, PF | 1 |
| Del Tacca, M | 1 |
| Chen, GY | 1 |
| Chang, TW | 1 |
| Chen, WC | 1 |
| Eiseman, AS | 1 |
| Flanagan, JC | 1 |
| Brooks, AB | 1 |
| Mitchell, EP | 1 |
| Pemberton, CH | 1 |
| Risum, S | 1 |
| Langer, SW | 1 |
| ROSSMAN, RE | 1 |
| KNOX, JM | 1 |
| FREEMAN, RG | 1 |
| LANE, M | 1 |
| MOERTEL, CG | 2 |
| REITEMEIER, RJ | 2 |
| HAHN, RG | 2 |
| HURLEY, JD | 1 |
| ANSFIELD, FJ | 1 |
| MCCAFFERY, JF | 1 |
| Childress, J | 1 |
| Lokich, J | 1 |
| Arikawa, R | 1 |
| Kanekura, T | 1 |
| Uchimiya, H | 1 |
| Kanzaki, T | 1 |
| Labandeira, J | 1 |
| Pereiro, M | 1 |
| Valdés, F | 1 |
| Toribio, J | 1 |
| Sorscher, SM | 1 |
| Fukushima, S | 1 |
| Hatta, N | 1 |
| Merk, HF | 1 |
| Wilkes, GM | 1 |
| Doyle, D | 1 |
| Abdel-Wahab, M | 1 |
| Abitbol, A | 1 |
| Lewin, A | 1 |
| Troner, M | 1 |
| Hamilton, K | 1 |
| Markoe, A | 1 |
| Lee, A | 1 |
| Ezzeldin, H | 1 |
| Fourie, J | 1 |
| Diasio, R | 1 |
| Woodruff, CA | 1 |
| Amrikachi, M | 1 |
| Hsu, S | 1 |
| Laing, ME | 1 |
| Laing, TA | 1 |
| Mulligan, NJ | 1 |
| Keane, FM | 1 |
| Gugerli, O | 1 |
| Leupin, N | 1 |
| Hague, JS | 1 |
| Ilchyshyn, A | 1 |
| Sroa, N | 1 |
| Bartholomew, DA | 1 |
| Magro, CM | 1 |
| Adachi, A | 1 |
| Nagai, H | 1 |
| Horikawa, T | 1 |
| Addeo, R | 1 |
| Montella, L | 1 |
| Baldi, A | 1 |
| Cennamo, G | 1 |
| Guarrasi, R | 1 |
| Faiola, V | 1 |
| Caraglia, M | 1 |
| Del Prete, S | 1 |
| Tol, J | 1 |
| Koopman, M | 1 |
| Rodenburg, CJ | 1 |
| Cats, A | 1 |
| Creemers, GJ | 1 |
| Schrama, JG | 1 |
| Erdkamp, FL | 1 |
| Vos, AH | 1 |
| Mol, L | 1 |
| Antonini, NF | 1 |
| Punt, CJ | 1 |
| Saif, MW | 1 |
| Seller, S | 1 |
| Diasio, RB | 1 |
| Di Fiore, F | 1 |
| Karlin, DA | 1 |
| Stroehlein, JR | 1 |
| Nixon, DW | 1 |
| Pirozzi, D | 1 |
| York, RM | 1 |
| Black, M | 1 |
| Lawson, DH | 1 |
| Epstein, E | 2 |
| Presant, CA | 2 |
| Ardalan, B | 2 |
| Multhauf, P | 1 |
| Chan, C | 1 |
| Staples, R | 1 |
| Green, L | 1 |
| Browning, S | 1 |
| Carr, BI | 1 |
| Chang, FF | 1 |
| Thayer, W | 1 |
| Legha, SS | 1 |
| Ajani, JA | 2 |
| Blumenschein, GR | 1 |
| Hortobagyi, GN | 1 |
| Buzdar, AU | 1 |
| Jamin, D | 1 |
| Jayaram, HN | 1 |
| Reed, WP | 1 |
| Morris, DM | 1 |
| Singer, Z | 1 |
| Kozaczka, A | 1 |
| Wilk, J | 1 |
| Janas, J | 1 |
| Herrmann, R | 1 |
| Spehn, J | 1 |
| Beyer, JH | 1 |
| von Franqué, U | 1 |
| Schmieder, A | 1 |
| Holzmann, K | 1 |
| Abel, U | 1 |
| Galentine, P | 1 |
| Sloas, H | 1 |
| Hargett, N | 1 |
| Cupples, HP | 1 |
| Fox, RM | 1 |
| Woods, RL | 1 |
| Tattersall, MH | 1 |
| Piper, AA | 1 |
| Sampson, D | 1 |
| Hann, SK | 1 |
| Rhoe, BS | 1 |
| Kang, WH | 1 |
| Park, YK | 1 |
| Kingsley, EC | 1 |
| Beard, JS | 1 |
| Smith, KJ | 1 |
| Skelton, HG | 1 |
| Prussick, R | 1 |
| Thibault, A | 1 |
| Turner, ML | 1 |
| Nadal, C | 1 |
| Pujol, RM | 2 |
| Randazzo, L | 1 |
| Marcuello, E | 1 |
| Alomar, A | 2 |
| Anderson, LL | 1 |
| Welch, ML | 1 |
| Grabski, WJ | 1 |
| Chiara, S | 1 |
| Nobile, MT | 1 |
| Barzacchi, C | 1 |
| Sanguineti, O | 1 |
| Vincenti, M | 1 |
| Di Somma, C | 1 |
| Meszaros, P | 1 |
| Rosso, R | 1 |
| Rocamora, V | 1 |
| Lopez-Pousa, A | 1 |
| Taberner, R | 1 |
| von Moos, R | 1 |
| Sauter, C | 1 |
| Sánchez-Pérez, J | 1 |
| Bartolomé, B | 1 |
| del Río, MJ | 1 |
| García-Díez, A | 1 |
| Schaefer, U | 1 |
| Micke, O | 1 |
| Schueller, P | 1 |
| Willich, N | 1 |
| Wang, HM | 1 |
| Ng, SH | 1 |
| Wang, CH | 1 |
| Liaw, CT | 1 |
| Chen, JS | 1 |
| Yang, TS | 1 |
| Chen, IH | 1 |
| Lubowe, II | 1 |
| Bernstein, T | 1 |
| Schlang, HA | 1 |
| Curtin, R | 1 |
| Cullen, SI | 1 |
| de Berker, D | 1 |
| Marren, P | 1 |
| Powell, SM | 1 |
| Ryan, TJ | 1 |
| Umstead, GS | 1 |
| Fryer, NL | 1 |
| Decker, DA | 1 |
| Grunberg, SM | 1 |
| Clay, C | 1 |
| Spicer, DV | 1 |
| Jordá, E | 1 |
| Galan, A | 1 |
| Betlloch, I | 1 |
| Ramon, D | 1 |
| Revert, A | 1 |
| Torres, V | 1 |
| Vukelja, SJ | 1 |
| Bonner, MW | 1 |
| McCollough, M | 1 |
| Cobb, PW | 1 |
| Gaule, DA | 1 |
| Fanucchi, PJ | 1 |
| Keeling, JH | 1 |
| Blackburn, WD | 1 |
| Alarcón, GS | 1 |
| Obrist, R | 1 |
| Haenggi, ST | 1 |
| Heiman, D | 1 |
| Obrecht, JP | 1 |
| Grattan, CE | 1 |
| Guerrier, CJ | 1 |
| Feldman, LD | 1 |
| Schosser, RH | 1 |
| Tennstedt, D | 1 |
| Lachapelle, JM | 1 |
| Shelley, WB | 1 |
| Shelley, ED | 1 |
| Guillaume, JC | 1 |
| Carp, E | 1 |
| Charpentier, P | 1 |
| André, P | 1 |
| Carde, P | 1 |
| Avril, MF | 1 |
| Patt, YZ | 1 |
| Peters, RE | 1 |
| Chuang, VP | 1 |
| Wallace, S | 1 |
| Claghorn, L | 1 |
| Mavligit, G | 1 |
| Caballero, GA | 1 |
| Ausman, RK | 1 |
| Quebbeman, EJ | 1 |
| Giai, M | 1 |
| De Fabiani, E | 1 |
| Lamberto, A | 1 |
| Cortese, P | 1 |
| Giardina, G | 1 |
| Levantine, A | 1 |
| Almeyda, J | 1 |
| Goldmann, L | 1 |
| Igelman, JM | 1 |
| Kitzmiller, K | 1 |
| Sams, WM | 1 |
| Farah, FS | 1 |
| Shbaklo, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer[NCT00079274] | Phase 3 | 3,397 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances[NCT01729481] | Phase 2 | 150 participants (Actual) | Interventional | 2012-07-31 | Active, not recruiting | ||
| Phase II Study of Erlotinib (TarcevaTM) Combined With Chemoradiation and Adjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer[NCT00313560] | Phase 2 | 48 participants (Actual) | Interventional | 2006-03-16 | Completed | ||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab[NCT00265811] | Phase 3 | 2,559 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Ancillary Study of miR-31-3p and miR-31-5p Expression Levels in Patients Enrolled in the PETACC-8 Study, and of the Predictive Role of miR-31-3p Expression Level on Clinical Outcomes of Patients Treated With Cetuximab[NCT03362684] | Phase 3 | 1,808 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Biomarker Validation Study of Linear Quantification of CD3 Positive Cells in Localized Colorectal Carcinomas, Based on the Cohort of Patient Included in PETACC8 International Phase III Trial (NCT00265811)[NCT02364024] | 856 participants (Actual) | Observational | 2005-11-30 | Completed | |||
| CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial[NCT00847912] | Phase 4 | 954 participants (Actual) | Interventional | 2009-06-26 | Completed | ||
| The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034] | 14 participants (Actual) | Interventional | 2020-08-04 | Terminated (stopped due to Principal Investigator retired before study completed.) | |||
| Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study[NCT00208546] | Phase 3 | 750 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A secondary endpoint for this study was to investigate the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Mutant KRAS Arm A | 67.1 |
| Mutant KRAS Arm D | 65.0 |
"The primary endpoint for this study was to compare the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS Arm A | 74.6 |
| Wild-type KRAS Arm D | 71.5 |
Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event-free rates (percentage) are report below for mutant KRAS patients. (NCT00079274)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Mutant KRAS Arm A | 87.9 |
| Mutant KRAS Arm D | 82.7 |
Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event free rates (percentage) are reported below for Wild-type KRAS Patients. (NCT00079274)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS Arm A | 87.3 |
| Wild-type KRAS Arm D | 85.6 |
The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years
| Intervention | percentage of patients (Number) |
|---|---|
| Mutant KRAS Arm A | 55.6 |
| Mutant KRAS Arm D | 72.3 |
The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years
| Intervention | percentage of patients (Number) |
|---|---|
| Wild-type KRAS Arm A | 51.1 |
| Wild-type KRAS Arm D | 73.3 |
Time from surgery to recurrence (NCT00313560)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| Erlotinib and EBRT After Pancreatectomy | 15.6 |
(NCT00313560)
Timeframe: up to 5 years
| Intervention | months (Median) |
|---|---|
| Erlotinib and EBRT After Pancreatectomy | 24.39 |
Quality of life (QOL) was assessed before CRT was started or during the first week of its administration (baseline [BL]), between completion of CRT and starting maintenance chemotherapy (time 1 [t1]), and within 3 months after completion of maintenance chemotherapy (time 2 [t2]). QLQ-PAN 26 questionnaire includes 26 questions, organized into 7 scales, with scores for each ranging from 0-100. Higher scores indicate worse health state. Therefore, decreasing (negative) scores indicate a better outcome. (NCT00313560)
Timeframe: 3 months
| Intervention | score on a scale (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pancreatic Pain (t1 vs. BL) | Pancreatic Pain (t2 vs. BL) | Pancreatic Pain (t2 vs. t1) | Digestive (t1 vs. BL) | Digestive (t2 vs. BL) | Digestive (t2 vs. t1) | Altered Bowel Habits (t1 vs. BL) | Altered Bowel Habits (t2 vs. BL) | Altered Bowel Habits (t2 vs. t1) | Jaundice (t1 vs. BL) | Jaundice (t2 vs. BL) | Jaundice (t2 vs. t1) | Body Image (t1 vs. BL) | Body Image (t2 vs. BL) | Body Image (t2 vs. t1) | Satisfaction with healthcare (t1 vs. BL) | Satisfaction with health care (t2 vs. BL) | Satisfaction with health care (t2 vs. t1) | Sexual function (t1 vs. BL) | Sexual function (t2 vs. BL) | Sexual function (t2 vs. t1) | |
| Erlotinib and EBRT After Pancreatectomy | -1.9 | -3.8 | 2.4 | -0.9 | -4.6 | -1.4 | 14.7 | 7.2 | -4.9 | -1.3 | -2 | 0 | -6.2 | -3.1 | -0.7 | 4.1 | 3.1 | 0 | -0.5 | 14.7 | 14.1 |
Quality of life (QOL) was assessed before chemoradiation therapy (CRT) was started or during the first week of its administration [baseline (BL)], between completion of CRT and starting maintenance chemotherapy [time 1 (t1)], and within 3 months after completion of maintenance chemotherapy [time 2 (t2)]. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) assesses quality of life on three domains: symptoms (score ranges from 7-14); function (score range 21-82); and global health status (score range 2-14). Higher or increasing scores mean worse outcomes; lower or decreasing scores mean better outcomes. (NCT00313560)
Timeframe: Up to 3 months after completion of maintenance chemotherapy
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global (Time 1 vs. BL) | Global (Time 2 vs. BL) | Global (Time 2 vs. Time 1) | Functional (F) - Physical (Time 1 vs. BL) | F - Physical (Time 2 vs. BL) | F - Physical (Time 2 vs. Time 1) | F - Role (Time 1 vs. BL) | F - Role (Time 2 vs. BL) | F - Role (Time 2 vs. Time 1) | F - Cognition (Time 1 vs. BL) | F - Cognition (Time 2 vs. BL) | F - Cognition (Time 2 vs. Time 1) | F - Emotional (Time 1 vs. BL) | F - Emotional (Time 2 vs. BL) | F - Emotional (Time 2 vs. Time 1) | F - Social (Time 1 vs. BL) | F - Social (Time 2 vs. BL) | F - Social (Time 2 vs. Time 1) | Financial (Time 1 vs. BL) | Financial (Time 2 vs. BL) | Financial (Time 2 vs. Time 1) | General Symptoms (GS) - Fatigue (Time 1 vs. BL) | GS - Fatigue (Time 2 vs. BL) | GS - Fatigue (Time 2 vs. Time 1) | GS - Nausea/Vomiting (Time 1 vs. BL) | GS - Nausea/Vomiting (Time 2 vs. BL) | GS - Nausea/Vomiting (Time 2 vs. Time 1) | GS - Pain (Time 1 vs. BL) | GS - Pain (Time 2 vs. BL) | GS - Pain (Time 2 vs. Time 1) | GS - Dyspnea (Time 1 vs. BL) | GS - Dyspnea Time 2 vs. BL) | GS - Dyspnea (Time 2 vs. Time 1) | GS - Insomnia (Time 1 vs. BL) | GS - Insomnia (Time 2 vs. BL) | GS - Insomnia (Time 2 vs. Time 1) | GS - Appetite Loss (Time 1 vs. BL) | GS - Appetite Loss (Time 2 vs. BL) | GS - Appetite Loss (Time 2 vs. Time 1) | GS - Constipation (Time 1 vs. BL) | GS - Constipation (Time 2 vs. BL) | GS - Constipation (Time 2 vs. Time 1) | GS - Diarrhea (Time 1 vs. BL) | GS - Diarrhea (Time 2 vs. BL) | GS - Diarrhea (Time 2 vs. Time 1) | |
| Erlotinib and EBRT After Pancreatectomy | 1 | -1.8 | 4.6 | 0.5 | -3.2 | -6.2 | -3.1 | -0.3 | -4.4 | -2.6 | 1.2 | -1.2 | -0.4 | 2.2 | -0.6 | 3.9 | 4.4 | -3.8 | 1.7 | 2.5 | 0 | 5.7 | 5.2 | 1.7 | 2.5 | 0 | 1.9 | 2.7 | 7.2 | 5 | 1.7 | 3.8 | 1.2 | -2.5 | 0 | 2.5 | -2.5 | -15 | -5 | -4.2 | -2.5 | 0 | 14.7 | 8.8 | -6.2 |
Number of participants experiencing adverse events during chemoradiation and during adjuvant chemotherapy, Grade 2 or higher, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. This is used to determine the Toxicity profile. (NCT00313560)
Timeframe: up to 3 years
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Grade 2 | Grade 3 | Grade 4 | |
| Adjuvant Gemcitabine Plus Erlotinib | 15 | 14 | 3 |
| Chemoradiation Plus Erlotinib | 24 | 15 | 1 |
(NCT00847912)
Timeframe: date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years
| Intervention | participants (Number) |
|---|---|
| Arm 1: 5-fluorouracil | 182 |
| Arm 2: Placebo, Vehicle Control | 177 |
Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically. (NCT00847912)
Timeframe: From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years
| Intervention | years (Median) |
|---|---|
| Arm 1: 5-fluorouracil | 3.37 |
| Arm 2: Placebo, Vehicle Control | 3.52 |
13 reviews available for fluorouracil and Dermatitis Medicamentosa
| Article | Year |
|---|---|
5-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review.
Topics: Dactinomycin; Drug Eruptions; Erythema Multiforme; Female; Fluorouracil; Humans; Hydatidiform Mole, | 2022 |
5-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review.
Topics: Dactinomycin; Drug Eruptions; Erythema Multiforme; Female; Fluorouracil; Humans; Hydatidiform Mole, | 2022 |
5-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review.
Topics: Dactinomycin; Drug Eruptions; Erythema Multiforme; Female; Fluorouracil; Humans; Hydatidiform Mole, | 2022 |
5-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review.
Topics: Dactinomycin; Drug Eruptions; Erythema Multiforme; Female; Fluorouracil; Humans; Hydatidiform Mole, | 2022 |
Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexrazoxane; Dim | 2014 |
[Toxic dermatitis due to capecitabine: presentation of 2 cases and literature review].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Eruptions; Fluorouracil; Hu | 2009 |
[Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2009 |
Systemic toxicity from occlusive therapy with topical 5-fluorouracil: a case report and review of the literature.
Topics: Abdominal Pain; Administration, Cutaneous; Antimetabolites, Antineoplastic; Chills; Diarrhea; Drug E | 2012 |
Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine | 2003 |
[Pharmacogenetics: Important aspects for dermatology].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Dapsone; Dermatology; Drug Eruptions; Fluorou | 2005 |
Palmar-plantar erythrodysesthesia.
Topics: Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Doxorubicin; Drug Eruptions; Erythema; Fem | 2005 |
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biotransformation; Deoxyuracil Nucleotides; Diarrhea; Di | 2004 |
Lipodermatosclerosis as a form of vascular compromise-associated radiation recall dermatitis: case report and a review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 2006 |
Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy.
Topics: Antimetabolites, Antineoplastic; Dermis; Drug Eruptions; Erythema; Fluorouracil; Follow-Up Studies; | 1998 |
Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Drug Eruptions; Fluorouracil; Humans; Infusions, Intravenous; Male; Photosensi | 1991 |
Drug reactions. XXIV. Cutaneous reactions to cytostatic agents.
Topics: Alopecia; Aminopterin; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Busulfan; Chlor | 1974 |
13 trials available for fluorouracil and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Drug Eruptions; Female | 2021 |
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycyti | 2018 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemot | 2013 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; C | 2015 |
Validation of Photograph-Based Toxicity Score for Topical 5-Fluorouracil Cream Application.
Topics: Administration, Cutaneous; Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous C | 2016 |
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
Topics: Adenocarcinoma; Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Ant | 2017 |
Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose- | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Stud | 2009 |
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Su | 2005 |
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2001 |
Local tissue reaction to intravenous fluorouracil and leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Fluorouracil; Humans; Infusions, Int | 1991 |
95 other studies available for fluorouracil and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cellulitis; Cetu | 2023 |
Severe necrotising inflammatory skin reaction to topical 5-fluorouracil.
Topics: Administration, Ophthalmic; Antimetabolites, Antineoplastic; Conjunctival Neoplasms; Drug Eruptions; | 2019 |
Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Drug | 2021 |
Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Drug Eruptions; Drug-Relat | 2021 |
Painful scrotal dermatitis secondary to topical 5-fluorouracil.
Topics: Administration, Topical; Aged; Drug Eruptions; Fluorouracil; Humans; Keratosis, Actinic; Male; Pain; | 2021 |
Tegafur/gimeracil/oteracil (TS-1)-induced erythroderma with an extensive mucosal involvement and hand-foot syndrome.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neop | 2017 |
Cutaneous Drug REactions: Annular, polycyclic erythematous exanthema in an oncology patient.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Generalized pustular drug eruption caused by topical 5-fluorouracil.
Topics: Administration, Cutaneous; Aged; Antimetabolites, Antineoplastic; Drug Eruptions; Female; Fluorourac | 2017 |
Cells to Surgery Quiz: July 2018.
Topics: Administration, Cutaneous; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Basal Cell; Diseas | 2018 |
Case of purpuric drug eruption probably induced by panitumumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Colonic Neoplasms; Drug Erupti | 2019 |
Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2013 |
Liver injury possibly related to drug interaction after liver transplant: a case report.
Topics: Adult; Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Chemical and Drug Induced Live | 2014 |
Photosensitive lichenoid drug eruption to capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Eruptions; Female; Fluorour | 2014 |
Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2014 |
5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles.
Topics: Adult; Antimetabolites, Antineoplastic; Antioxidants; Biopsy; Clobetasol; Diagnosis, Differential; D | 2014 |
A perplexing case.
Topics: Aged, 80 and over; Drug Eruptions; Fluorouracil; Genital Diseases, Male; Groin; Humans; Male; Skin U | 2016 |
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorecta | 2017 |
Pyogenic granuloma-like lesions caused by capecitabine therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Deoxycytidine; Drug Eruptions; Fingers; Fl | 2008 |
Subacute cutaneous lupus erythematosus induced by capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Erupt | 2009 |
Exudative, nonhealing scalp: a complication of systemic chemotherapy with capecitabine and bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Calling attention to radiation recall reactions. Simultaneous occurrence of a Recall Dermatitis after CMF application in two separate sites irradiated 10 years apart.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 2012 |
Symmetrical drug-related intertriginous and flexural exanthema secondary to topical 5-fluorouracil.
Topics: Administration, Cutaneous; Drug Eruptions; Exanthema; Fluorouracil; Hand Dermatoses; Humans; Immunos | 2012 |
Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans.
Topics: Aged; Anaphylaxis; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycy | 2012 |
Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alleles; Antimetabolites, Antineop | 2012 |
Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma, Neur | 2013 |
Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Colorectal Neoplasms | 2002 |
Erosion of psoriatic plaques: an uncommon side-effect of neoadjuvant 5-fluorouracil treatment of colon cancer.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Eruptions; Fluorouracil | 2002 |
Pyogenic granuloma-like lesions during capecitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Drug Eruptions; Fluorouracil; Fo | 2002 |
Cutaneous recall reactions with systemic fluorouracil.
Topics: Administration, Topical; Aged; Antimetabolites, Antineoplastic; Drug Eruptions; Esophageal Neoplasms | 2003 |
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
Topics: Alopecia; Antimetabolites, Antineoplastic; Area Under Curve; Diarrhea; Drug Eruptions; Female; Fever | 2002 |
Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil.
Topics: Adult; Antimetabolites, Antineoplastic; Black or African American; Cohort Studies; Drug Eruptions; E | 2003 |
[Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Dose-Response R | 2003 |
CLINICOPATHOLOGIC CONFERENCE.
Topics: Black People; Bromides; Diagnosis, Differential; Drug Eruptions; Fluorouracil; Granuloma; Humans; Ke | 1964 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Humans; Leuko | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
Topics: Adenocarcinoma; Agranulocytosis; Biomedical Research; Diarrhea; Diverticulitis; Drug Eruptions; Fluo | 1964 |
Cutaneous hand and foot toxicity associated with cancer chemotherapy.
Topics: Antineoplastic Agents; Docetaxel; Doxorubicin; Drug Eruptions; Erythema; Fluorouracil; Foot; Hand; H | 2003 |
A case of prurigo-type drug eruptions due to UFT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Drug Eruptions; Fe | 2003 |
Intermittent topical 5-fluorouracil is effective without significant irritation in the treatment of actinic keratoses but prolongs treatment duration.
Topics: Administration, Topical; Adult; Aged; Drug Administration Schedule; Drug Eruptions; Fluorouracil; Hu | 2004 |
Penile involvement with hand-foot syndrome.
Topics: Antineoplastic Agents; Drug Eruptions; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; | 2004 |
Atypical moles in a patient undergoing chemotherapy with oral 5-fluorouracil prodrug.
Topics: Aged; Antimetabolites, Antineoplastic; Diagnosis, Differential; Drug Eruptions; Fluorouracil; Humans | 2004 |
Zosteriform metastatic transitional cell carcinoma.
Topics: Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Transitional | 2005 |
Eosinophilic pustular folliculitis induced by chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Eruptions; | 2006 |
[Blisters unlike others].
Topics: Aged; Antimetabolites, Antineoplastic; Blister; Capecitabine; Deoxycytidine; Drug Eruptions; Female; | 2006 |
Lichenoid photosensitive eruption due to capecitabine chemotherapy for metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Eruptions | 2007 |
Anti-SSA/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions.
Topics: Aged; Antimetabolites, Antineoplastic; Autoantibodies; Biopsy; Diagnosis, Differential; Drug Eruptio | 2007 |
Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Eruptions; Fluorouraci | 2007 |
Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; D | 2008 |
[Non-resectable metastases from colorectal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
Rash, nephritis, hypertension, and haemolysis in patient on 5-fluorouracil, doxorubicin, and mitomycin-C.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Doxorubicin; Drug Eruptions; Drug Therapy, Combinati | 1980 |
Dermatologic changes after systemic cancer therapy.
Topics: Adult; Antineoplastic Agents; Bleomycin; Cyclophosphamide; Cytotoxins; Dactinomycin; Doxorubicin; Dr | 1981 |
Hidden fluorouracil applications as a cause of dermatitis and erosions.
Topics: Administration, Topical; Aged; Drug Eruptions; Facial Dermatoses; Female; Fluorouracil; Humans; Male | 1983 |
Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
Topics: Adult; Aged; Aspartic Acid; Carcinoma; Colonic Neoplasms; Drug Administration Schedule; Drug Eruptio | 1983 |
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; | 1984 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
Maculopapular eruption resulting from systemic administration of 5-fluorouracil.
Topics: Aged; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil; Hand Dermatoses; Humans | 1984 |
[Non-hematologic adverse effects of cytostatic drugs].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Diarrhea; Drug Eruptions; Female; | 1984 |
Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colonic Neoplasms; Drug | 1984 |
Bilateral cicatricial ectropion following topical administration of 5-fluorouracil.
Topics: Administration, Topical; Aged; Cicatrix; Drug Eruptions; Ectropion; Facial Dermatoses; Fluorouracil; | 1981 |
Allopurinol modulation of fluorouracil toxicity.
Topics: Allopurinol; Drug Eruptions; Drug Therapy, Combination; Fluorouracil; Hematologic Diseases; Humans; | 1981 |
Self limited dermal invasion of keratinocytes in maculopapular eruptions after systemic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basement Membrane; Breast Neoplasms; Carcinoma, Intr | 1993 |
5-Fluorouracil dermatitis prophylaxis with a nicotine patch.
Topics: Administration, Cutaneous; Aged; Drug Eruptions; Female; Fluorouracil; Humans; Nicotine | 1994 |
Combination chemotherapy with 5-fluorouracil, folinic acid, and alpha-interferon producing histologic features of graft-versus-host disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Erythema; Female; Fluorouracil; Graf | 1993 |
Recall of cutaneous toxicity from fluorouracil.
Topics: Adult; Drug Eruptions; Fluorouracil; Humans; Immunologic Memory; Male | 1993 |
Systemic contact dermatitis from 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Dermatitis, Allergic Contact; Drug Eruptions; Fluorouracil; Humans; | 1996 |
Allergic contact dermatitis and reactivation phenomenon from iontophoresis of 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Dermatitis, Allergic Contact; Drug Eruptions; Fluorouracil; H | 1997 |
Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1997 |
Does intermittent "pulse" topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation?
Topics: Administration, Cutaneous; Antimetabolites; Dermatitis; Drug Administration Schedule; Drug Eruptions | 1998 |
[Photosensitization caused by 5-fluorouracil (5-FU)].
Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Diagnosis, Differential; Drug Eruptions; F | 1999 |
Allergic contact dermatitis from 5-fluorouracil with positive intradermal test and doubtful patch test reactions.
Topics: Dermatitis, Allergic Contact; Drug Eruptions; Female; Fluorouracil; Humans; Immunosuppressive Agents | 1999 |
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2000 |
Cutaneous drug reaction case reports: from the world literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Capecitabine; Carbamates; Ceftriaxone; Clonidine; Deoxyc | 2002 |
Fluorouracil for skin blemishes and lines.
Topics: Dermatitis, Contact; Drug Eruptions; Fluorouracil; Humans | 1977 |
Skin reactions to 5-fluorouracil.
Topics: Breast Neoplasms; Drug Eruptions; Drug Hypersensitivity; Female; Fluorouracil; Humans; Injections, I | 1977 |
Inflammation of malignant skin involvement with fluorouracil.
Topics: Breast Neoplasms; Drug Eruptions; Female; Fluorouracil; Humans; Middle Aged | 1977 |
Topical fluorouracil therapy for precancers and cancers of the skin.
Topics: Administration, Topical; Drug Eruptions; Fluorouracil; Humans; Keratosis; Precancerous Conditions; S | 1979 |
Contact sensitivity to the stearyl alcohol in Efudix cream (5-fluorouracil).
Topics: Aged; Dermatitis, Contact; Drug Eruptions; Fatty Alcohols; Female; Fluorouracil; Humans; Keratosis | 1992 |
Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Drug Eruptions; Drug Tolerance; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1991 |
Painful, red hands. A side effect of 5-fluorouracil by continuous perfusion.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Eruptions; Female; Fluorouracil; Hand Dermatoses; Humans; Mi | 1991 |
Toxic response to topical fluorouracil in two rheumatoid arthritis patients receiving low-dose, weekly methotrexate.
Topics: Aged; Arthritis, Rheumatoid; Drug Eruptions; Drug Synergism; Fluorouracil; Humans; Keratosis; Male; | 1990 |
Localized skin toxicity from 5-fluorouracil after paravenous infusion of leukovorin calcium.
Topics: Drug Eruptions; Fluorouracil; Humans; Injections, Subcutaneous; Leucovorin; Liver Neoplasms; Male; M | 1990 |
Reaction to topical fluorouracil of secondary lymphedema.
Topics: Aged; Drug Eruptions; Facial Dermatoses; Female; Fluorouracil; Humans; Lymphedema; Ointments | 1985 |
Fluorouracil-associated dermatitis of the hands and feet.
Topics: Adult; Drug Eruptions; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male | 1985 |
Toxic reaction to prolonged high-dose fluorouracil.
Topics: Drug Eruptions; Fluorouracil; Humans | 1986 |
Allergic contact dermatitis to 5-fluorouracil.
Topics: Adult; Drug Eruptions; Fluorouracil; Humans; Male; Skin Diseases; Warts | 1987 |
Scrotal dermatitis caused by 5-fluorouracil (Efudex).
Topics: Adolescent; Adult; Condylomata Acuminata; Dermatitis, Contact; Drug Eruptions; Fluorouracil; Genital | 1988 |
[Cutaneomucous adverse effects of continuous infusion of 5-fluorouracil: 12 cases].
Topics: Adult; Drug Eruptions; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Infusions, In | 1988 |
Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; C | 1985 |
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil | 1985 |
[Secondary effects of adjuvant therapy].
Topics: Alopecia; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1985 |
Investigative studies with DMSO in dermatology.
Topics: Animals; Dermatomycoses; Dimethyl Sulfoxide; Drug Eruptions; Fluocinolone Acetonide; Fluorouracil; G | 1967 |
Untoward response with topical fluorouracil.
Topics: Aged; Carcinoma, Basal Cell; Drug Eruptions; Female; Fluorouracil; Humans; Keratosis; Male; Middle A | 1968 |
Combination chemotherapy in gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall | 1970 |
The treatment of premalignant and malignant skin lesions with 5-fluorouracil.
Topics: Drug Eruptions; Female; Fluorouracil; Humans; Keratosis; Male; Precancerous Conditions; Skin; Skin N | 1971 |